Skip to main content

Synchron's enrollment pause leaves US and Australian studies active, with Canada terminated

Official trial records distinguish a recruitment pause from a terminated study. They also leave a separate question: what evidence validates the investigational BCI system.

A silver wire-mesh tube and a thin cable on a dark laboratory tray under blue light.
AI-generated conceptual illustration, not a photograph of Stentrode: TechKili / Cloudflare FLUX.2 klein.
Share this article:
In this article

Synchron has paused enrollment in its next-generation Stentrode studies, according to WIRED's November 12, 2026 report. The important distinction is between stopping recruitment and ending a study: current public records do not give all three national programs the same status.

The company told WIRED that a lead-related performance problem prompted a voluntary pause. That account does not establish the exact day recruitment stopped. The US and Australian registry updates were posted before the report, on November 5 and 6 respectively.

Three records describe different situations

TechKili checked the sponsor-submitted ClinicalTrials.gov records on November 15. They describe an investigational system intended to translate motor-related brain signals into control of digital devices for people with upper-limb motor impairment.

Study Current registry status What the record establishes
INTENT, United States Active, not recruiting Early feasibility study; latest update posted November 5.
FOCUS-AUS, Australia Active, not recruiting Study remains active; latest update posted November 6.
FOCUS-CAN, Canada Terminated Record cites insufficient recruitment, one enrolled participant and September 25 completion.

The Canadian record supplies its own reason for termination. It should not be recast as evidence that the same hardware issue ended that study. Likewise, a registry status describes study activity; it is not a technical root-cause analysis or an independent finding about device safety.

Enrollment status is different from evidence of benefit

Synchron's current website identifies the system as investigational, says its clinical benefit has not been validated and states that it is not approved for commercial use in any geography. That boundary matters more to someone following assistive technology than demonstrations of individual tasks.

A device intended to turn neural signals into commands still needs evidence that the complete system performs usefully over time. The registry descriptions set out what the studies investigate; they do not themselves demonstrate that the proposed benefit has been achieved.

The next useful update would connect a documented change in recruitment status with evidence about the revised system. For readers assessing this development, keep those two questions separate: whether enrollment has reopened, and what published results establish. Neither a projected milestone nor a company demonstration can answer both.

Sources